Fig. 4. Subgroup analyses for differences in number of responders with (a) 30% reduction and (b) 50% reduction in pain intensity from baseline (score 0-100). CBD, cannabidiol; CBDV, cannabidivarin; CI, confidence interval; THC, tetrahydrocannabinol.